A head mounted device stimulator for optogenetic retinal prosthesis

Soltan, Ahmed; Barrett, John M.; Maaskant, Pleun; Armstrong, Niall; Al-Atabany, Walid; Chaudet, Lionel; Neil, Mark A. A.; Sernagor, Evelyne; Degenaar, Patrick

doi:10.1088/1741-2552/aadd55

Cited by 37 publications

(22 citation statements)

References 52 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our devices emit at a center wavelength of 445 nm, which is typical of GaN LEDs widely used in optogenetics. Although this wavelength overlaps well with the peak absorption of channelrhodopsin, shorter wavelengths increase the risk of photochemical damage in tissue, especially in the context of retinal implants (Wu et al, 2006; Soltan et al, 2018). Thus, a longer wavelength which also overlaps with channelrhodopsin absorption, such as 470 nm, may be preferred.…”

Section: Discussionmentioning

confidence: 99%

High Density, Double-Sided, Flexible Optoelectronic Neural Probes With Embedded μLEDs

et al. 2019

View full text Add to dashboard Cite

Optical stimulation and imaging of neurons deep in the brain require implantable optical neural probes. External optical access to deeper regions of the brain is limited by scattering and absorption of light as it propagates through tissue. Implantable optoelectronic probes capable of high-resolution light delivery and high-density neural recording are needed for closed-loop manipulation of neural circuits. Micro-light-emitting diodes (μLEDs) have been used for optical stimulation, but predominantly on rigid silicon or sapphire substrates. Flexible polymer neural probes would be preferable for chronic applications since they cause less damage to brain tissue. Flexible μLED neural probes have been recently implemented by flip-chip bonding of commercially available μLED chips onto flexible substrates. Here, we demonstrate a monolithic design for flexible optoelectronic neural interfaces with embedded gallium nitride μLEDs that can be microfabricated at wafer-scale. Parylene C is used as the substrate and insulator due to its biocompatibility, compliance, and optical transparency. We demonstrate one-dimensional and two-dimensional individually-addressable μLED arrays. Our μLEDs have sizes as small as 22 × 22 μm in arrays of up to 32 μLEDs per probe shank. These devices emit blue light at a wavelength of 445 nm, suitable for stimulation of channelrhodopsin-2, with output powers greater than 200 μW at 2 mA. Our flexible optoelectronic probes are double-sided and can illuminate brain tissue from both sides. Recording electrodes are co-fabricated with μLEDs on the front- and backside of the optoelectronic probes for electrophysiology recording of neuronal activity from the volumes of tissue on the front- and backside simultaneously with bi-directional optical stimulation.

show abstract

Section: Discussionmentioning

confidence: 99%

High Density, Double-Sided, Flexible Optoelectronic Neural Probes With Embedded μLEDs

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The XR-tests in conscious-state transition offer an opportunity to evaluate retinal-support as part of psychiatric comfort targets [75] or, to evaluate potential pharmaceutical risk of overdosing a dementia patients.…”

Section: Schematic Example Of a Selected Nucleic-network Xr Model Using The Human Connectome Project (Hcp) Hcp Hosts Detailed Neuromorphomentioning

confidence: 99%

The Need for XR-Measurement of Decision-Making Decline and Conscious-State Transition Impairment before Nonvoluntary Euthanization of Dementia Patients

Campbell¹

2021

Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care

View full text Add to dashboard Cite

Non-voluntary euthanization of dementia patients, the majority of whom are severely conscious-state transition-impaired because of both high levels of anti-somnogenic cytokine levels and circadian disruption, indicates the lack of measurement of decision-making decline and conscious-state transition in palliative care settings. This chapter explains why and how to setup medically-meaningful tests to collect these measurements based on environmental-interactive parameters of nonconscious testing in circadian calibrated XR or virtual reality platforms. It also mentions worthy opportunities in relationship to the Human Connectome Project, including the Alzheimer’s Disease Connectome Project.

show abstract

“…Advances in channelrhodopsin properties have also combined with improvements in paired light-stimulating devices used to stimulate the exogenous rhodopsins that decrease photochemical damage (Cideciyan et al, 2016;Sengupta et al, 2016;B. Yan, Vakulenko, Min, Hauswirth, & Nirenberg, 2016;Soltan et al, 2018). The safety and tolerability of optogenetic technologies are currently being explored in three separate phase I/IIa clinical trials (Table 3).…”

Section: Optogenetic Therapiesmentioning

confidence: 99%

“…Since its initial development, recent advancements have produced channelrhodopsins variants with significantly improved light sensitivity (Chaffiol et al, 2017; Ganjawala, Lu, Fenner, Abrams, & Pan, 2019) and at safer wavelengths (Sengupta et al, 2016). Advances in channelrhodopsin properties have also combined with improvements in paired light‐stimulating devices used to stimulate the exogenous rhodopsins that decrease photochemical damage (Cideciyan et al, 2016; Sengupta et al, 2016; B. Yan, Vakulenko, Min, Hauswirth, & Nirenberg, 2016; Soltan et al, 2018). The safety and tolerability of optogenetic technologies are currently being explored in three separate phase I/IIa clinical trials (Table 3).…”

Section: The Future Of Ocular Gene Therapy: Tackling New Genes With Nmentioning

confidence: 99%

The new landscape of retinal gene therapy

Pennesi

2020

American J of Med Genetics Pt C

View full text Add to dashboard Cite

Novel therapeutics for inherited retinal dystrophies (IRDs) have rapidly evolved since groundbreaking clinical trials for LCA due to RPE65 mutations led to the first FDAapproved in vivo gene therapy. Since then, advancements in viral vectors have led to more efficient AAV transduction and developed other viral vectors for gene augmentation therapy of large gene targets. Furthermore, significant developments in gene editing and RNA modulation technologies have introduced novel capabilities for treatment of autosomal dominant diseases, intronic mutations, and/or large genes otherwise unable to be treated with current viral vectors. We highlight strategies currently being evaluated in gene therapy clinical trials and promising preclinical developments for IRDs.

show abstract

A head mounted device stimulator for optogenetic retinal prosthesis

Cited by 37 publications

References 52 publications

High Density, Double-Sided, Flexible Optoelectronic Neural Probes With Embedded μLEDs

High Density, Double-Sided, Flexible Optoelectronic Neural Probes With Embedded μLEDs

The Need for XR-Measurement of Decision-Making Decline and Conscious-State Transition Impairment before Nonvoluntary Euthanization of Dementia Patients

The new landscape of retinal gene therapy

Contact Info

Product

Resources

About